Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F11%3A10100653" target="_blank" >RIV/00216208:11150/11:10100653 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11160/11:10100653 RIV/00179906:_____/11:10100653
Result on the web
<a href="http://www.sciencedirect.com/science/article/pii/S1043661811000727" target="_blank" >http://www.sciencedirect.com/science/article/pii/S1043661811000727</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.phrs.2011.03.008" target="_blank" >10.1016/j.phrs.2011.03.008</a>

Result language
angličtina
Original language name
Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis
Original language description
In this study, we hypothesized whether atorvastatin treatment affects endoglin/ALK-1/p-Smad1/VEGF expression in the aorta and endoglin levels in serum in ApoE/LDLR double knockout mice. In conclusion, it has been demonstrated that atorvastatin increasesendoglin/ALK-1/p-Smad1/VEGF expression in aorta and decreases the size of atherosclerotic lesions, suggesting that activation of this endothelial-protective pathway might support the antiatherogenic effects of atorvastatin. Moreover, atorvastatin concurrently decreased serum levels of endoglin suggesting that monitoring of endoglin levels in blood might represent an important marker of the progression and/or treatment of atherosclerosis.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FR - Pharmacology and apothecary chemistry
OECD FORD branch
—

Project
—
Continuities
Z - Vyzkumny zamer (s odkazem do CEZ)<br>S - Specificky vyzkum na vysokych skolach

Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)